Biotech Values

[biocqr]

Re: OncoImmune and SACCOVID...

OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

https://www.biospace.com/article/releases/oncoimmune-s-saccovid-cd24fc-exhibits-superb-therapeutic-efficacy-a-potential-breakthrough-in-treating-severe-and-critical-covid-19/

“The interim analysis shows safety and outstanding therapeutic efficacy of SACCOVIDTM. The results indicate that patients who received SACCOVIDTM had a 60% better chance to achieve clinical recovery than those who received placebo (P=0.005). The median time to recovery was 6 days for patients treated with SACCOVIDTM compared with 10 days in the placebo group. In addition, the risk of death or respiratory failure is reduced by more than 50%,” said Dr. Pan Zheng, MD, PhD, Chief Medical Officer and co-founder of OncoImmune. Since the trial did not exclude other experimental therapeutics, many participants also received Remdesivir and/or corticosteroids including dexamethasone. Among them, those who were treated with SACCOVIDTM and Remdesivir recovered 7 days earlier than those who received Remdesivir and placebo (median time to recovery 6 days vs 13 days). Those who were treated with SACCOVIDTM and corticosteroids recovered 10 days earlier than those who received corticosteroids and placebo (median time to recovery 5 days vs 15 days). More detailed information about the trial results will be released as soon as the study is submitted to peer-reviewed medical journals.